Curis, Inc. · NASDAQ:CRIS
Curis — Investor Presentation (January 2024)
17 slides from Curis's investor presentation, January 2024
Slide 1: Corporate Presentation January 2024
Corporate Presentation January 2024
Slide 2: Cautionary Note Regarding Forward Looking Statements and Disclaimers
Cautionary Note Regarding Forward Looking Statements and Disclaimers This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “expect(s),” “beli
Slide 3: Corporate Overview
Corporate Overview Leader of IRAK4 Inhibition; Developing Emavusertib with Broad Application in Oncology Investment Emavusertib is a novel, highly-active IRAK4 inhibitor with potential cornerstone utility in heme and solid tumors Full development program underway in front-line and end-stage AML/MDS;
Slide 4: IRAK4 is a Novel Anti-Cancer Target
IRAK4 is a Novel Anti-Cancer Target Oncogenic IRAK4 activity promotes inflammation and impairs T cell function • Upregulation of IRAK4 in tumors leads to activation of NF-κB, JNK, and MAPK1,2 • IRAK-4 upregulation is associated with increased phenotypically exhausted TILs, MDSCs, increased CD4+ T re
Slide 5: Emavusertib Has A Unique Molecular Fingerprint
Emavusertib Has A Unique Molecular Fingerprint The NCI selected emavusertib for Targeted design is specifically engineered to be best-in-class NCI-sponsored research and clinical studies of IRAK4 Emavusertib Emavusertib Kinase Interaction Map Binding Affinity FLT3 Target Kd nM IRAK4 IRAK1 12,000 IRA
Slide 6: Emavusertib in Leukemia
Emavusertib in Leukemia
Slide 7: Emavusertib Has a Unique Mechanism of Action
Emavusertib Has a Unique Mechanism of Action The two primary targets of emavusertib are independent drivers of cancer IRAK4 FLT3 spliceosome mutations drive overexpression of IRAK4-Long, which genetic mutations cause constitutive activation of FLT3 constitutively activates the myddosome, driving NF-
Slide 8: Preclinical Data
Preclinical Data Rationale for monotherapy and combination with azacitidine/venetoclax Monotherapy in IRAK4 Monotherapy in FLT3 Combination with Aza/Ven 100% “Concomitant targeting of IRAK1 or IRAK4, alongside FLT3, is the most effective means to overcome the adaptive resistance incurred when target
Slide 9: Compelling Initial Clinical Data
Emavusertib Compelling Initial Clinical Data Showing clear single agent activity where expected in AML/MDS clinical studies 8 Targeted AML Patients 7 Targeted AML Patients All comers, All dose levels w/ Spliceosome Mutation* w/ FLT3 Mutation* 100% ** ** ** 80% 0% 0% 60% Patients % Change in Marrow B
Slide 10: Emavusertib in Leukemia (AML/MDS)
Emavusertib in Leukemia (AML/MDS) The ideal candidate to address the two largest genetically-defined populations in AML/MDS Emavusertib addresses the two largest genetically-defined populations in AML/MDS: 1 1) IRAK4-L (>50% of population) 2 2) FLT3 (>25% of population) Next Steps TakeAim Leukemia S
Slide 11: Emavusertib in Lymphoma
Emavusertib in Lymphoma
Slide 12: Emavusertib in Lymphoma
Emavusertib in Lymphoma Combination therapy provides complimentary inhibition of two pathways that drive NF-κB NFκB Biology: Clinical Strategy: Two Pathways Drive NHL/CLL Block both pathways with Combination Therapy BCR and TLR Pathways independently drive NF-κB overactivity In preclinical testing,
Slide 13: ASH 2023 Clinical Data in Lymphoma
ASH 2023 Clinical Data in Lymphoma All patients achieved decreases in tumor burden, including multiple complete responses • 19 treated patients, 11 of whom had received prior BTKi treatment, demonstrated anti-cancer activity • Median treatment duration was 96 days (range 21-613 days), suggesting acc
Slide 14: ASH 2023 Clinical Data in PCNSL
ASH 2023 Clinical Data in PCNSL All patients achieved decreases in tumor burden, including multiple complete responses PCNSL combination with ibrutinib 0% 5 evaluable PCNSL patients previously treated with BTKi -20% demonstrated anti-cancer activity, with 3 patients achieving CR and one % Change fro
Slide 15: Clinical Strategy in Lymphoma
Clinical Strategy in Lymphoma Emavusertib is the ideal candidate to combine with BTKi to maximize downregulation of NF-κB • Patients are currently treated with BTKi because it downregulates NF-κB • Two pathways drive NF-κB: Next Steps TakeAim Lymphoma Study 1) BCR Pathway: addressed by blocking BTK
Slide 16: Corporate Overview
Corporate Overview Leader of IRAK4 Inhibition; Developing Emavusertib with Broad Application in Oncology Investment Emavusertib is a novel, highly-active IRAK4 inhibitor with potential cornerstone utility in heme and solid tumors Full development program underway in front-line and end-stage AML/MDS;
Slide 17: End of Corporate Presentation
End of Corporate Presentation NASDAQ: CRIS